Olopatadine 0.2% ophthalmic solution: the first ophthal once-daily dosing

Expert Opinion on Drug Metabolism and Toxicology 4, 453-461

DOI: 10.1517/17425255.4.4.453

Citation Report

#	Article	IF	Citations
1	Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. Clinical Ophthalmology, 2009, 3, 329.	1.8	7
2	The management of allergic eye diseases in primary eye care. Contact Lens and Anterior Eye, 2009, 32, 260-272.	1.7	26
3	Olopatadine 0.1% and 0.2% ophthalmic solution for the management of ocular allergy. Expert Review of Ophthalmology, 2010, 5, 287-296.	0.6	5
4	Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert Opinion on Pharmacotherapy, 2010, 11, 969-981.	1.8	23
5	Antihistamines in Ocular Allergy: Are They All Created Equal?. Current Allergy and Asthma Reports, 2011, 11, 205-211.	<b>5.</b> 3	25
6	Immunomodulators for conjunctivitis. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 550-557.	2.3	28
7	A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model. Journal of Asthma and Allergy, 2013, 6, 43.	3.4	29
8	Difluprednate 0.05% Versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: A Phase III, Multicenter, Randomized Study., 2014, 55, 2993.		59
9	Bromfenac Ophthalmic Solution 0.07% Dosed Once Daily for Cataract Surgery. Ophthalmology, 2014, 121, 25-33.	5.2	33
10	Allergic Eye Disease. Pediatric Clinics of North America, 2014, 61, 607-620.	1.8	20
11	Development and validation for the determination of olopatadine in human plasma by liquid chromatography–tandem mass spectrometry: application to a bioequivalence study of Ilhwa Allotadine tablet (olopatadine HCl 5Âmg). Journal of Pharmaceutical Investigation, 2015, 45, 285-292.	<b>5.</b> 3	2
12	Treating Allergic Conjunctivitis: A Once-daily Medication that Provides 24-hour Symptom Relief. Allergy and Rhinology, 2016, 7, ar.2016.7.0158.	1.6	12
13	Mast cell stabilisers. European Journal of Pharmacology, 2016, 778, 158-168.	<b>3.</b> 5	97
14	Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis. Clinical Ophthalmology, 2017, Volume 11, 1089-1097.	1.8	5
15	Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2%. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 593-605.	1.8	3
16	Novel Polyvinyl Pyrrolidone–Loaded Olopatadine HCl–Laden Doughnut Contact Lens to Treat Allergic Conjunctivitis. Journal of Pharmaceutical Sciences, 2020, 109, 1714-1724.	3.3	21
17	Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan;) Tj ETQq0 0 Pharmacology and Translational Science, 2020, 3, 1391-1421.	0 rgBT /O 4.9	verlock 10 Tf ! 9
18	Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis. American Journal of Ophthalmology, 2021, 229, 288-300.	3.3	8

#	Article	IF	Citations
19	The Effect of Olopatadine 0.1% Ophthalmic Solution on Ocular and Nasal Symptoms in Patients with Seasonal Allergic Rhino-Conjunctivitis. Journal of the Royal Medical Services, 2013, 20, 45-50.	0.0	0
20	Comparative Study of 0.1% Olopatadine vs 0.05% Cyclosporine in Patients of Recalcitrant Vernal Keratoconjunctivitis. International Journal of Advanced and Integrated Medical Sciences, 2016, 1, 139-142.	0.0	1
21	The Effect Of Topical Antihistamines Used Single Dose Daily in Allergic Conjunctivitis. Open Ophthalmology Journal, 2018, 12, 330-337.	0.2	0
22	Immune Mechanisms, Pathology, and Management of Allergic Ocular Diseases. , 2020, , 229-277.		0
23	Etiology and pharmacotherapy of ocular surface allergic diseases. , 2022, , 403-422.		0